DOCSLIB.ORG

Patch Test Concentrations and Vehicles for Testing Contact Allergens

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patch Test Concentrations and Vehicles for Testing Contact Allergens 49_907_928 05.11.2005 12:13 Uhr Seite 907 Chapter 49 Patch Test Concentrations 49 and Vehicles for Testing Contact Allergens Anton C. De Groot, Peter J. Frosch Patch testing is a relatively safe and reasonably reli- Guidelines for testing the patient’s own contact able method for identifying contact allergens in pa- materials are provided in Chap. 50. tients with contact dermatitis. It has been clearly Table 2 lists alphabetically all chemicals men- shown that patch testing is necessary in the majority tioned in this book with their test concentrations and of patients with eczema [1]. The technique of patch vehicles (sometimes two concentrations are suggest- testing is described in Chap. 22. ed when insufficient data are available) as suggested All patients are tested with the European standard by the various authors. All allergens commercially series,containing the most frequent contact allergens available are also listed with their supplier(s), their in European countries (Table 1). Often, standard se- test concentrations, and vehicles as supplied. It ries patch testing is not enough, and additional aller- should be appreciated that for a considerable num- gens or potential allergens need to be tested, based ber of allergens, the concentrations vary between on the patient’s history and clinical examination. Ex- suppliers. Table 3 provides a list of test concentra- amples are products and chemicals to which the pa- tions for groups of chemicals as suggested by various tient is exposed occupationally or in his or her home authors in this book. Table 4 finally is an alphabetical environment. Test series containing the most fre- listing of commonly used abbreviations and their full quent allergens in certain products (preservatives, chemical synonyms. fragrances, dental materials, plastics and glues, me- dicaments) or in certain occupations (hairdressing, pesticides, oil and cooling fluid) are very helpful.Ap- References proximately 510 patch test materials are commercial- ly available from Hermal (Reinbek, Germany, www. 1. Rycroft RJG (1990) Is patch testing necessary? In: hermal.de), Chemotechnique Diagnostics (Malmö, Champion RH, Pye RJ (eds) Recent advances in dermatol- ogy, vol 8. Churchill Livingstone, Edinburgh, pp 101–111 Sweden, www.chemotechnique.se) and Brial Allergen 2. De Groot AC (1994) Patch testing. Test concentrations and (Greven, Germany, www.brial.com). vehicles for 3700 chemicals, 2nd edn. Elsevier, Amsterdam For other chemicals and products, the investigator 3. Rietschel RL, Fowler JF Jr (eds) (1995) Fisher’s contact der- must decide how to apply them as a patch test.Chem- matitis, 4th edn. Williams and Wilkins, Baltimore, Md. icals usually need to be diluted,and it is of the utmost 4. Adams RM (1990) Occupational skin disease, 2nd edn. Saunders, Philadelphia, Pa. importance to use an appropriate patch test concen- 5. De Groot AC, Weijland JW, Nater JP (1994) Unwanted tration and vehicle to avoid both false-negative and effects of cosmetics and drugs used in dermatology, 3rd false-positive (irritant) reactions. The most useful edn. Elsevier, Amsterdam reference source for documented test concentrations 6. Kanerva L, Elsner P,Wahlberg JE, Maibach HI (eds) (2000) Handbook of occupational dermatology. Springer, Berlin and vehicles of chemicals, groups of chemicals and Heidelberg New York products is the book Patch testing. Test concentra- tions and vehicles for 3700 chemicals [2]. Other useful lists are provided in recent textbooks on contact der- matitis [3–6]. 49_907_928 05.11.2005 12:13 Uhr Seite 908 908 Anton C. De Groot, Peter J. Frosch Table 1. The European standard series Chemical Test concentration and vehicle Metals Cobalt chloride 1% pet. Nickel sulfate 5% pet. Potassium dichromate 0.5% pet. Rubber chemicals Thiuram mix 1% pet. Dipentamethylenethiuram disulfide (0.25%) Tetramethylthiuram disulfide (0.25%) 49 Tetraethylthiuram disulfide (0.25%) Tetramethylthiuram monosulfide (0.25%) N-Isopropyl-N´-phenyl-p-phenylenediamine 0.1% pet. Mercapto mix 2% pet. N-Cyclohexylbenzothiazyl sulfenamide (0.5%) Dibenzothiazyl disulfide (0.5%) Mercaptobenzothiazole (0.5%) Morpholinyl mercaptobenzothiazole (0.5%) Mercaptobenzothiazole 2% pet. Medicaments Budesonide 0.01% pet. Benzocaine 5% pet. Neomycin sulfate 20% pet. Clioquinol® 5% pet. Tixocortol pivalate 0.1% pet. Cosmetic ingredients Balsam of Peru (Myroxylon pereirae) 25% pet. 5-Chloro-2-methylisothiazol-3-one/2-methylisothiazol-3-one (MCI/MI) 0.01% aq. Colophonium (rosin) 20% pet. Formaldehyde 1% aq. Fragrance mix (incl. 5% sorbitan sesquioleate) 8% pet. α-Amylcinnamaldehyde (1%) Cinnamal(dehyde) (1%) Cinnamyl alcohol (1%) Eugenol (1%) Geraniol (1%) Hydroxycitronellal (1%) Iso-eugenol (1%) Oak moss absolute (Evernia prunastri) (1%) Paraben mix 16% pet. Butylparaben (4%) Ethylparaben (4%) Methylparaben (4%) Propylparaben (4%) p-Phenylenediamine free base 1% pet. Quaternium-15 1% pet. Wool wax alcohols (lanolin alcohol) 30% pet. Hydroxymethylpentylcyclohexenecarboxaldehyde (Lyral®) 5% pet. Miscellaneous p-tert-Butylphenol formaldehyde resin 1% pet. Epoxy resin 1% pet. Primin 0.01% pet. Sesquiterpene lactone mix 0.1% pet. Alantolactone (0.033%) Dehydrocostus lactone (0.033%) Costunolide (0.033%) 49_907_928 05.11.2005 12:13 Uhr Seite 909 Patch Test Concentrations and Vehicles Chapter 49 909 Table 2. Test concentrations, vehicles and commercial availability of contact allergens. [Alc. Alcohol, aq. water, DMSO dimethyl sulfoxide, Glyc. glycerine, MEK methyl ethyl ketone (butanone), o.o. olive oil, pet. petrolatum, prop. glyc. propylene glycol.] [icr Immediate contact reactions reported (Chaps 5 and 26), de drug eruption with positive patch test reported (Chap. 24), fde fixed drug eruption with positive patch test reported (Chap. 24), ph photosensitivity reported (Chaps 6, 17 and 27), phde photosensi- tive drug eruption with positive photopatch test reported (Chaps 6, 17, 24 and 27)] Allergen Test Concentration and vehicle Suppliers Trolab Chemo Brial Abietic acid (icr) 10% pet. + + + Acebutolol hydrochloride 2% pet. Aceclofenac 1% pet Acetylsalicylic acid (icr) 10% pet. Achillea millefolium (yarrow extract) 1% pet. + + Acid black 48 (CI 65005) 1% pet. Acid red 14 (azorubine) 0.1% alc. Acid red 118 (CI 26410) 5% pet. + Acid red 359 5% pet. + Acid violet 17 (CI 42650) 1% pet. Acid yellow 36 (CI 13065, metanil yellow) 1% pet. + + + Acid yellow 61 (CI 18968) 5% pet. Actarit (phde) 1% pet Aciclovir (fde) 5% pet. Alantolactone (icr) 0.33% pet. Alclometasone-17,21-dipropionate 1% alc. 1% pet. Alcohol, ethyl (icr) 10% aq. Alimemazine tartrate see Trimeprazine tartrate Allantoin 0.5% aq. Althiazide (phde) 10% pet. or aq. Aluminum (icr) Pure Aluminum chloride hexahydrate 2% pet. Allylisopropylacetylurea See Apronalide Amalgam 5% pet. Amalgam alloying metals 20% pet. + + Amalgam non gamma 2 5% pet. Amcinonide 1% alc. 0.1% pet. 0.1% pet. Amerchol ® L-101 See Lanolin alcohol and paraffinum liquidum Amethocaine See Tetracaine hydrochloride Amikacin sulfate 20% pet. 4-Aminoantipyrine See Ampyrone p-Aminoazobenzene (Solvent yellow 1, CI 11000) 0.25% pet 1% pet. + 1% pet. ε-Aminocaproic acid 1% aq. Amino-4-N, N-diethylaniline sulfate (TSS Agfa®) 1% pet. 2-2-(Aminoethoxy)ethanol See Diglycolamine Amino-4-N-ethyl-N-(methanesulfon- 1% pet. + + aminoethyl)-m-toluidine (CD 3) Aminoglycosides (de) 20% pet. m-Aminophenol 1% pet. + + + p-Aminophenol (CI 76550) (icr) 1% pet. + + + Aminophylline (fde) 10% pet. Amitriptyline (phde) 5% pet. Amlexanox (fde) 1% pet. Ammoniated mercury 1% pet. + + + Ammonium bituminosulfonate See Ichthammol Ammonium heptamolybdate 1% aq. Ammonium hexachloroplatinate (icr) 0.1% aq. + Ammonium persulfate (icr) 2.5% pet. + + + Ammonium tetrachloroplatinate (icr) 0.25% pet. + 0.25% aq. + Ammonium thioglycolate 1% pet., fresh 2.5% aq. 1% pet. Amorolfine 1% pet. Ampicillin (icr) 5% pet. + Ampiroxicam (phde) 1% pet. Amprolium hydrochloride 10% aq. Ampyrone (4-aminoantipyrine) (icr) 10% pet. 49_907_928 05.11.2005 12:13 Uhr Seite 910 910 Anton C. De Groot, Peter J. Frosch Table 2. Continued Allergen Test Concentration and vehicle Suppliers Trolab Chemo Brial α-Amylcinnamaldehyde (icr) 2% pet. 1% pet. + 1% pet. Amylocaine hydrochloride 5% pet + Anethole 5% pet. Aniline 1% pet. + Antazoline 1% pet. Anthemis nobilis (chamomilla romana) 1% pet. Antipyrine (phenazone) (de) 5% pet. 49 Apronalide (allylisopropylacetylurea) (fed) 5% pet. Arnica montana (arnica extract) 0.5% pet. + + Arsanilic acid 10% pet. Atenolol (de) 10% pet. Atranorin (ph) 0.1% pet. Atropine sulfate 1% aq. or pet + (aq.) + (aq.) Azathioprine 1% pet. Azidamfenicol 2% pet. Azodicarbonamide 0.5% pet. Azodiisobutyrodinitrile 1% pet. Azorubine See Acid red 14 Bacitracin (icr) 20% pet. + 5% pet. + Bacitracin zinc 20% pet. Balsam of Peru See Myroxylon pereirae Balsam of Tolu See Myroxylon toluiferum Basic brown 1 See Bismarck Brown R Basic red 46 1% pet. Beech tar See Fagus sylvatica Befunolol 1% aq. Benomyl 0.1–1% pet. Benoxinate See Oxybuprocaine Benzaldehyde (icr) 5% pet. + + Benzalkonium chloride (BAK) 0.01–0.1% aq. 0.1% pet. 0.1% aq. 0.1% pet. Benzamine lactate 1% pet. 2-Benzimidazolethiol 1% pet. (2-mercaptobenzimidazole) Benzisothiazolinone (BIT) (ph) 0.1% pet. + 0.05% pet. + Benzocaine (icr) (ph) 5% pet. + + + Benzodiazepines (de) 1–5% aq. or pet. Benzoic acid (icr) (ph) 5% pet. 5% pet.; 1% alc./glyc. Benzoin resin see Styrax benzoin Benzophenone-3 (oxybenzone) (ph) 10% pet. + + + Benzophenone-4 (sulisobenzone) (ph) (icr) 10% pet. + + + Benzophenone-10 (mexenone) (ph) 10% pet. + IH-Benzotriazole 1% pet.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • Safety Assessment of Benzyl Salicylate As Used in Cosmetics
    Safety Assessment of Benzyl Salicylate As Used in Cosmetics Status: Draft Report for Panel Review Release Date: November 9, 2018 Panel Meeting Date: December 3-4, 2018 The 2018 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Alice Akinsulie, Scientific Writer/Analyst. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] Commitment & Credibility since 1976 Memorandum To: CIR Expert Panel Members and Liaisons From: Alice Akinsulie, Scientific Analyst/Writer Date: November 9, 2018 Subject: Draft Safety Assessment of Benzyl Salicylate as Used in Cosmetics Enclosed is the Draft Report of the Safety Assessment of Benzyl Salicylate as Used in Cosmetics. (It is identified as bensal122018rep in the pdf document.) On October 9, 2018, CIR issued the Scientific Literature Review (SLR) for this ingredient. According to the Dictionary, Benzyl Salicylate is reported to function mainly as a fragrance ingredient and light stabilizer. The Personal Care Products Council (Council) provided concentration of use survey data for the light stabilizer function (only) of Benzyl Salicylate. The results indicate that the light stabilizer concentrations of use for Benzyl Salicylate falls in the IFRA Standards for use of Benzyl Salicylate as a fragrance ingredient (identified as bensal122018data).
    [Show full text]
  • Subject Index
    52_1107_1136_SI 16.11.2005 9:35 Uhr Seite 1107 Subject Index A – tape 264, 368, 940 α-adjustment 154 AAS, see atomic absorption spectrophotometry adrenocorticotrophic hormone (ACTH) 21 abietic acid 909, 943 adverse drug reaction 401 abrasion 174, 283 aeroallergen 391 absorption through appendage 169 – atopic eczema 391 α-acaridial 329 – avoidance 391 accident 889 aerospace 726 acebutolol hydrochloride 909 African aceclofenac 909 –ebony783 acetaldehyde 943 – mahagony 783 acetone 118, 666 – red padauk wood 783 acetylacetone 697 Agave acetylsalicylic acid 84, 909 – americana 354 Achillea millefolium (yarrow extract) 909 – tequilana 225 aciclovir 909 age 279 acid 110 agent orange 806 – black 48 (CI 65005) 909 AGEP 404 – dye 689 Agfa TSS 355 – halogenated 259 aggravation 204 –hydrochloric261 agricultural worker 272 –nitric261 agriculture 725 –red AICD, see activation-induced cell death – – 14 (azorubine) 909 airborne – – 118 (CI 26410) 909 – allergic contact dermatitis 218, 228, 315, 467, 477, 484, 598, ––359909 627, 654, 788 – violet 17 (CI 42650) 909 – contact urticaria 753, 758 – yellow – irritant contact dermatitis 625 – – 36 (CI 13065, metanil yellow) 909 aircraft manufacture 560 – – 61 (CI 18968) 909 airway symptom 520 acitretin 341 alachlor 953 acneiform alantolactone 55, 789, 909, 954 – folliculitis 229 alclometasone-17,21-dipropionate 909 –lesion265 alclometasone-17-propionate 58 acrodermatitis enteropathica 241 alcohol, see also ethyl 909 acrovesicular dermatitis 401 aldehyde 110, 607, 886 acrylamide 592, 944 algicide 562 acrylate
    [Show full text]
  • Safety Assessment of Benzyl Salicylate As Used in Cosmetics
    Safety Assessment of Benzyl Salicylate As Used in Cosmetics Status: Scientific Literature Review for Public Comment Release Date: October 9, 2018 Panel Meeting Date: December 3-4, 2018 All interested persons are provided 60 days from the above release date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Executive Director, Dr. Bart Heldreth. The 2018 Cosmetic Ingredient Review Expert Panel members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Alice Akinsulie, Scientific Writer/Analyst. © Cosmetic Ingredient Review 1620 L Street, NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] INTRODUCTION This scientific literature review is the initial step in preparing a safety assessment of Benzyl Salicylate as used in cosmetic formulations.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al
    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Multiple Targets of Salicylic Acid and Its Derivatives in Plants and Animals
    REVIEW published: 26 May 2016 doi: 10.3389/fimmu.2016.00206 Multiple Targets of Salicylic Acid and Its Derivatives in Plants and Animals Daniel F. Klessig1*, Miaoying Tian2 and Hyong Woo Choi1 1 Boyce Thompson Institute, Cornell University, Ithaca, NY, USA, 2 Department of Plant and Environmental Protection Sciences, University of Hawaii at Manoa, Honolulu, HI, USA Salicylic acid (SA) is a critical plant hormone that is involved in many processes, includ- ing seed germination, root initiation, stomatal closure, floral induction, thermogenesis, and response to abiotic and biotic stresses. Its central role in plant immunity, although extensively studied, is still only partially understood. Classical biochemical approaches and, more recently, genome-wide high-throughput screens have identified more than two dozen plant SA-binding proteins (SABPs), as well as multiple candidates that have yet to be characterized. Some of these proteins bind SA with high affinity, while the affinity of others exhibit is low. Given that SA levels vary greatly even within a particular plant species depending on subcellular location, tissue type, developmental stage, and with respect to both time and location after an environmental stimulus such as infection, the presence of SABPs exhibiting a wide range of affinities for SA may provide great Edited by: flexibility and multiple mechanisms through which SA can act. SA and its derivatives, Brigitte Mauch-Mani, Université de Neuchâtel, Switzerland both natural and synthetic, also have multiple targets in animals/humans. Interestingly, Reviewed by: many of these proteins, like their plant counterparts, are associated with immunity or Robin Katrina Cameron, disease development. Two recently identified SABPs, high mobility group box protein McMaster University, Canada and glyceraldehyde 3-phosphate dehydrogenase, are critical proteins that not only serve Taras P.
    [Show full text]
  • Imports of Benzenoid Chemicals and Products in 1977
    IMPORTS OF BENZENOID CHEMICALS, AND PRODUCTS 1977 United States General Imports of Intermediates, Dyes, Medicinals, Flavor and Perfume Materials, and Other Finished Benzenoid Products Entered in 1977 Under Schedule 4, Part 1, of the . Tariff Schedules of the United States USITC PUBLICATION 900 . JULY 1978 United States International Trade Commission I Washington, D.C. 20436 UNITED ST ATES INTERNATIONAL· TRADE. COMMISSION COMMISSIONERS Joseph 0. Parker, Chairman Bill Alberger, Vice Chairman George M. Moore Catherine Bedell ltalo H. Ablondi Daniel Minchew Kenneth R. Mason, Secretary to the Commission OFFICE OF INDUSTRIES Norris A. Lynch, Director This report was principally prepared by Frances Battle, Virginia Bailey, Judy Bryant, Ralph Gray, Sharon Greenfield, Mildred Higgs, Kenneth Kozel, Ross Lewis, Linda Mudd, and Loretta Willis of the Energy and Chemical Division. Antomatic Data Processing imput was provided by James Gill and Dean Stout. Address all communications to Office of the Secretary United States International Trade Commission Washington, D.C. 20436 For Release Contact: Mr. James O'Connor July 21, 1978 (202) 523-0496 USITC 78-076 UNITED STATES INTERNATIONAL TRADE COMMISSION RELEASES FIGURES ON IMPORTS OF BENZENOID CHEMICALS AND PRODUCTS IN 1977 The U.S. International Trade Commission today issued a re~ port on U.S. imports of benzenoid chemicals and products in 1977. The report includes data on articles entered under schedule 4, parts lB and lC, of the Tariff Schedules of the United States. It provides detailed statistics on imports of 2,670 products, including benzenoid intermediates, dyes, organic pigments, medic­ inals and pharmaceuticals, flavor and pe~fume materials, and other benzenoid products.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • RISK PROFILE of Phenyl Salicylate
    RISK PROFILE Phenyl salicylate C A S N o . 1 1 8 - 55- 8 Date of reporting 05.06.201 2 Content of document 1. Identification of substance .................................................................... p. 1 2. Uses and origin ................................................................................ p. 2 3. Regulation ............................................................................................. p. 3 4. Relevant toxicity studies .................................................................... p. 4 5. Exposure estimates and critical NOAEL/NOEL ........................................... p. 5 6. Other sources of exposure than cosmetic products .............................. p. 8 7. Assessment ............................................................................................. p. 9 8. Conclusion ............................................................................................. p. 10 9. References ............................................................................................. p. 11 10. Annexes ............................................................................................. p. 13 1. Identification of substance Chemical name (IUPAC): Phenyl -2-hydroxybenzoate INCI Phenyl salicylate Other name Salol CAS No. 118-55-8 EINECS No. 204-259-2 Molecular formula C13H10O3 Chemical structure Molecular weight 214.22 g/mol Contents (if relevant) Physiochemical properties Appearance: solid, white crystalline substance Density: 1.25 g/cm3 Risk profile Phenyl Salicylate Page 1 of
    [Show full text]